Literature DB >> 1747397

Solubility and acid-base behaviour of midazolam in media of different pH, studied by ultraviolet spectrophotometry with multicomponent software.

R Andersin1.   

Abstract

The solubility of midazolam is less than 0.1 mg ml-1 at neutral pH and it increases considerably in acidic media. A pKa value of 6.04 at 24 +/- 1 degree C was calculated from the solubility data. In acidic media midazolam is reversibly converted to the corresponding benzophenone (open-ring form). The extent of this reaction was investigated by assaying the two compounds simultaneously by UV spectrophotometry with multicomponent software. The structure of the benzophenone derivative was verified by IR, MS and 1H and 13C NMR spectrometry.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1747397     DOI： 10.1016/0731-7085(91)80246-6

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN： 0731-7085            Impact factor:   3.935


  9 in total

1.  Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model II: Verification of the model for passive placental permeability drugs.

Authors:  Zufei Zhang; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2017-01-03       Impact factor: 3.922

Review 2.  Sedation for critically ill or injured adults in the intensive care unit: a shifting paradigm.

Authors:  Derek J Roberts; Babar Haroon; Richard I Hall
Journal:  Drugs       Date:  2012-10-01       Impact factor: 9.546

3.  Stability of parenteral midazolam in an oral formulation.

Authors:  S E Walker; H A Grad; D A Haas; A Mayer
Journal:  Anesth Prog       Date:  1997

4.  Recycling Unused Midazolam Drug as Efficient Corrosion Inhibitor for Copper in Nitric Acid Solution.

Authors:  Andrea Kellenberger; Delia Andrada Duca; Mircea Laurentiu Dan; Mihai Medeleanu
Journal:  Materials (Basel)       Date:  2022-04-16       Impact factor: 3.748

5.  The Effects of pH on the Structure and Bioavailability of Imidazobenzodiazepine-3-Carboxylate MIDD0301.

Authors:  M S Rashid Roni; Guanguan Li; Brandon N Mikulsky; Daniel E Knutson; Md Yeunus Mian; Nicolas M Zahn; James M Cook; Douglas C Stafford; Leggy A Arnold
Journal:  Mol Pharm       Date:  2020-02-26       Impact factor: 4.939

6.  Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans.

Authors:  Annika Elbe; Kathrin Isabelle Foerster; Antje Blank; Peter Rose; Jürgen Burhenne; Walter Emil Haefeli; Gerd Mikus
Journal:  Eur J Clin Pharmacol       Date:  2022-03-03       Impact factor: 3.064

7.  Brain-targeting delivery of MMB4 DMS using carrier-free nanomedicine CRT-MMB4@MDZ.

Authors:  Yimeng Du; Jing Gao; Hui Zhang; Xiaohui Meng; Dong Qiu; Xiang Gao; Aiping Zheng
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

8.  Hydrochloride Salt of the GABAkine KRM-II-81.

Authors:  Md Yeunus Mian; Branka Divović; Dishary Sharmin; Kamal P Pandey; Lalit K Golani; V V N Phani Babu Tiruveedhula; Rok Cerne; Jodi L Smith; Xingjie Ping; Xiaoming Jin; Gregory H Imler; Jeffrey R Deschamps; Arnold Lippa; James M Cook; Miroslav M Savić; James Rowlett; Jeffrey M Witkin
Journal:  ACS Omega       Date:  2022-07-27

Review 9.  Strategies to Improve Drug Strength in Nasal Preparations for Brain Delivery of Low Aqueous Solubility Drugs.

Authors:  Patrícia C Pires; Márcio Rodrigues; Gilberto Alves; Adriana O Santos
Journal:  Pharmaceutics       Date:  2022-03-08       Impact factor: 6.321
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.